WAC and ASP of Neulasta (pegfilgrastim) biosimilars U.S. 2022

Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022

WAC and ASP of Neulasta (pegfilgrastim) biosimilars in the U.S. 2022

Last update:

Oct 31, 2022

Author:

��ƽ�� Research Department

Region:

Worldwide

Survey time period:

From 01/01/2022 to 31/12/2022

As of July 2022, biosimilar Nyvepria (pegfilgrastim-apgf) launched at an average sales price of 16 percent higher than Neulasta's ASP, while the biosimilar drug Fulphila (pegfilgrastim-jmdb) launched at an average sales price of six percent less than Neulasta's. This statistic illustrates the wholesale acquisition cost and average sales price of Neulasta (pegfilgrastim) biosimilars in the United States.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022

Get in touch with us for additional information

��ƽ��